Peg Squier

  • Citations Per Year
Learn More
86 Background: In a phase III study in MBC, nab-P showed activity across lines of therapy. nab-P is approved for MBC at 260 mg/m2 every 3 weeks (q3w). This analysis evaluated outcomes with use of nab-P in MBC by schedule and line of therapy in a U.S. community setting. METHODS A multicenter, retrospective cohort analysis was conducted using iKnowMed(More)
  • 1